viewBioCorRx Inc.

BioCorRx on growth fast-track with robust pipeline, programs for substance use disorders, and weight loss


BioCorRx received a $5.7 million grant this year from the National Institute on Drug Abuse for developing its flagship BICX102 naltrexone implant

BioCorRx - BioCorRx on growth fast-track with robust pipeline, MAT programs for substance use recovery, weight loss

Quick facts: BioCorRx Inc.

Price: 2.8 USD

Market: OTCQB
Market Cap: $14.84 m
  • Working to create a naltrexone implant, BICX102, to help people kick their addiction to opioids and alcohol
  • Licenses its BioCorRx Recovery Program, a MAT program for substance use disorders to healthcare providers and clinics
  • UnCraveRx combines an app that provides fitness and group support with anti-craving medication from independent medical practices 

What BioCorRx does:

BioCorRx Inc (OTCMKTS:BICX) is a healthcare company that's focused on developing advanced treatment solutions for addiction, weight loss, and other related disorders.

The company is led by Brady Granier, CEO and president of BioCorRx, who was born in the heart of Cajun Country in southeast Louisiana where he started working at the age of 11 to support his single mother and younger brother.  

It's personal for Granier, who has family members with addiction in their past. He has also worked as a nurse in the emergency room at White Memorial Hospital in Los Angeles. Granier, who has gone onto spearheading marketing campaigns for national brands, has sharpened BioCorRx’s focus on providing alcohol and opioid addiction treatment programs to rehab centers in the US.

Through its subsidiaries, the Anaheim, California-based company licenses the BioCorRx Recovery Program, a medication-assisted treatment (MAT) program for substance use to healthcare providers and clinics.

The first component of the BioCorRx Recovery Program typically consists of an outpatient implant procedure prescribed and performed by a licensed physician. The implant delivers naltrexone which reduces cravings for alcohol and opioids. The program can also be used for those receiving other forms of MAT, such as injectable naltrexone or buprenorphine in any form. Secondly, the program relies on cognitive behavioral therapy modules and peer support built around the use of medications deemed appropriate by a treatment provider for treating substance use disorder.

Similarly, the UnCraveRx Weight Loss Program is also a medically-assisted program that addresses food cravings combined with a concierge on-demand app that provides access to virtual lifestyle support, fitness and nutrition.

The company conducts R&D under its subsidiary BioCorRx Pharmaceuticals. It is developing BICX101, an extended-release injectable formulation of naltrexone. BioCorRx is also working to create an implant, named BICX102 that will help people fight their addiction to both opioids and alcohol.  

The BICX102 implant uses naltrexone, a drug already approved by the FDA, as an every-day pill or a once-per-month shot. Naltrexone blocks receptors in the brain so that opioids or alcohol may become less appealing, and if used, it could block some of the effects of those substances. The company is creating an implant designed to last three months which should address medication adherence issues often seen with other forms of naltrexone. BICX102 will be surgically implanted in a person's adipose tissue, usually in stomach fat, and dissolve slowly over three months and not need to be removed as its completely adsorbed by the body.

How is it doing:

Experts say America is in the throes of an opioid epidemic. Nearly 23.5 million Americans are addicted to drugs, alcohol and misuse opioids, according to the Substance Abuse and Mental Health Services Administration.

As a result, the over $40 billion addiction treatment market is seeking radical transformation in the shape of effective new treatments. BioCorRX is leading the change by offering a two-pronged approach to the treatment of substance abuse addiction.

Medication-assisted treatment (MAT) — the use of medication combined with counselling and behavioral therapies — which is the BioCorRx method, is one of the major pillars of the federal response to the opioid epidemic in America.

In a positive sign, BioCorRx recently received a $5.7 million grant from the National Institute on Drug Abuse (NIDA) for the development of BICX102. It will last two years, which the company says will fund the research through the development of the implant and some early testing.

The grant validates the clinical potential of BICX102 which has several potential advantages over other medications used for treatment of substance use disorder. One, is that it fully biodegrades, eliminating the need to remove and replace it as seen with other implants. It also should maintain therapeutic plasma levels for up to three months, said the company, while future versions are expected to last longer. The company’s goal is to give a person a longer time period to address the underlying reasons for their disorder without the intrusive cravings interfering.

BioCorRx is seeking a more rapid and cost-effective 505(b)(2) regulatory pathway for its naltrexone implant. Towards that end, it has partnered with IRISYS to manufacture and develop BICX102.

The company has a master services agreement with Charles River Laboratories which is conducting preclinical studies of BICX102. If things go according to plan, the company aims to start human studies next year.

In April, the company raised $6 million at a premium to its market price from two investors.

The company has also been backed by Alpine Creek Capital which first invested $2.5 million when BioCorRx had a market cap of just $3 million. Alpine Creek Capital followed up their initial investment with an additional tranche in the first quarter of 2017.

BioCorRx said a senior secured convertible promissory note of $4.16 million with BICX Holding, an entity controlled by Alpine Creek Capital, was recently converted into 2.22 million shares of common stock in order to simplify the company's capital structure and boost its balance sheet.

Significantly, the timely conversion eliminated $4.16 million of liabilities from the company’s balance sheet.  

Inflection points:

BioCorRX’s goal is to get Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to go into human trials of BICX102, it's lead pipeline candidate. The company is hoping this will come to fruition in 2020.

The company’s new medically-assisted UnCraveRx Weight Loss Program is likely to be a key growth revenue driver as it looks to expand its provider network.

UnCraveRx, which launched in October, is a 12-week program that combines a sustained-release anti-craving medication with a virtual concierge app that provides access to on-demand virtual fitness, nutrition and behavior lifestyle group support. 

The company is likely to get strong traction from its new UnCraveRx Weight Loss Program, coupled with the private placement funding and the $5.7 million NIDA grant for BICX102. All these drivers should help the promising healthcare company accelerate its product development and growth strategy.

It’s no secret that BioCorRx is eying a Nasdaq listing and has enhanced its capital structure and improved its balance sheet to prepare for the planned up-listing to the tech-laden exchange. The move will give the company access to a wider investor base.

What the boss says:

In an interview with Proactive, BioCorRx Inc CEO Brady Granier said: “We have a clean balance sheet, no toxic loans, strong management, independent board, strategic investors, products/programs that do work, government funding for R&D. We operate lean and are poised for growth.”

He added: “We feel undervalued based on the accomplishments of this year alone with raising funds at a premium to market plus the NIDA grant award. We raised about $6-$7 million in the last year alone at a premium.”

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioCorRx Inc. named herein, including the promotion by the Company of BioCorRx Inc. in any Content on the Site, the Company receives from said...



Full interview: BioCorRx presents new preclinical data showing VDM-001...

BioCorRx Inc (OTCMKTS:BICX) CEO Brady Granier tells Proactive early data suggests its drug therapy may prevent overdoses from fentanyl. Granier says while VDM-001 is still in its early days, with more validation studies to come, the drug candidate could represent an alternative to naloxone in...

on 12/04/2019

6 min read